2,421 trials (keyword fallback)
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Adult Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 0; 0.15; 0 proportion of participants
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
Medulloblastoma
Primary: Event-free Survival (EFS) — 76.3; 84.9; 85.8; 85.8 probability of 3 year EFS
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Desmoplastic/Nodular Medulloblastoma · Medulloblastoma · Medulloblastoma With Extensive Nodularity
Primary: Progression-free Survival (PFS) — 52.0 percent probability
Brain and Central Nervous System Tumors · Long-term Effects Secondary to Cancer Therapy in Children
Primary: Cumulative Incidence of Ototoxicity — 12; 16; 16; 15 percentage of participants
Brain Tumor · Central Nervous System Tumor · Childhood Germ Cell Tumor
Primary: Incidence of Hearing Loss — 14; 31 Patients
Relapsed or Refractory Solid Tumors
Primary: Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO)…
Brain and Central Nervous System Tumors
Primary: Feasibility
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Neuroblastoma · Medulloblastoma
Primary: Number of Participants With Related Adverse Events as a Measure of Safety and Tolerability — 45 Participants
Childhood Cerebral Anaplastic Astrocytoma · Childhood Oligodendroglioma · Childhood Spinal Cord Neoplasm
Primary: Objective Response Rate Sustained for ≥ 8 Weeks — 0; 0; 0; 0 participants